Care pathways through the transition

What this cluster is, and is not

Read this as the page on the site where the answer is not a Solgar supplement and is also not a treatment recommendation. The question women in this window arrive with is who to see, where, and what to ask — and the honest answer carries a UK-specific framing. NICE NG23, updated in 2024, governs UK menopause prescribing whether the consultation is NHS or private; the British Menopause Society sets the specialist accreditation that distinguishes a clinician whose practice centres on menopause from one for whom it sits at the edge. [1] [3] The cards below sort the UK pathway landscape into NHS, private and telehealth, and describe what each can and cannot offer. The clinical decision is yours to make with a clinician.

Three threads of the literature and the published UK record are mature enough to write about with confidence for a UK woman in this window: NICE NG23 itself as the governing clinical guideline, with the BMS clinician tools sitting alongside it for specialist accreditation; [1] [3] the worldwide epidemiological evidence on MHT and breast cancer risk that quantifies a known clinical trade-off in numbers a reader can take to a consultation; [4] and the Wellbeing of Women survey programme alongside the UK Parliament Women and Equalities Committee evidence sessions, which document the access gap that has shaped the UK private and telehealth markets. [6] [7] Read the cards below against those three threads — and against your own family history, baseline risk and symptom burden, in a conversation with a clinician.

What the published record shows

The findings below sort the UK menopause-care landscape into the governing clinical guideline, the specialist accreditation framework, the quantified trade-off behind the most-asked HRT question, and the access gap that has shaped where women actually end up booking. The cards beneath them are written against UK availability, BMS-accredited clinicians, transparent fees, and NICE-aligned prescribing scope.

Research findings

1. NICE NG23 frames perimenopause diagnosis as clinical and sets the prescribing scope a UK GP works inside.

   The 2024 update of NICE NG23 directs UK clinicians to diagnose perimenopause clinically in women over 45 with vasomotor symptoms and a change in cycle, and outlines the menopausal hormone therapy options a GP can offer in primary care alongside non-hormonal alternatives. The guideline also defines when a referral to a specialist is appropriate — atypical presentations, premature ovarian insufficiency under 40, contraindications that complicate first-line MHT, and persistent symptoms after a reasonable trial. Reading the guideline is the cleanest way to understand what an NHS appointment can and cannot offer before booking.

   Source: NICE NG23 · 2024 update · Clinical guideline, England & Wales

2. The British Menopause Society defines the UK accreditation pathway for specialist menopause care.

   The BMS Principles and Practice of Menopause Care training and the BMS-accredited specialist register are the UK quality marker for clinicians whose practice centres on the menopausal transition. The 2024 BMS clinician tools update sets out investigation, diagnosis and management standards aligned with NICE NG23, and lists the credentials a reader can ask about before a private consultation. Whether a clinic is private, NHS or telehealth, the question worth asking is whether the clinician seeing you holds the BMS specialist accreditation.

   Source: BMS · 2024 clinician tools · UK specialist accreditation framework

3. Menopausal hormone therapy carries quantifiable, time-and-formulation-dependent breast cancer risk that the worldwide epidemiological evidence describes in numbers.

   The Collaborative Group on Hormonal Factors in Breast Cancer 2019 individual-participant meta-analysis (108,647 postmenopausal breast cancer cases) reports that current oestrogen-progestagen users carry a relative risk of 1.60 (95% CI 1.52–1.69) at years 1–4 and 2.08 (2.02–2.15) at years 5–14, with oestrogen-only preparations carrying smaller but still positive relative risks (1.17 at years 1–4, 1.33 at years 5–14). Translated into population terms: 5 years of oestrogen-plus-daily-progestagen use starting at age 50 corresponds to approximately one extra breast cancer per 50 users by age 69. Vaginal oestrogen preparations were not associated with excess risk. The framing for a UK reader booking an HRT consultation is that the trade-off is quantified, and the right place to read it against your own profile is with a clinician.

   Source: Lancet · 2019 · CGHFBC · Meta-analysis, n = 108,647 cases

4. UK menopause-care access is uneven across NHS, private and telehealth pathways, and the published Wellbeing of Women survey work documents the gap.

   The Wellbeing of Women Menopause Workplace Pledge survey programme and the 2022–2024 series of UK Parliament Women and Equalities Committee evidence sessions document the access gap: women report lengthy waits for an NHS GP menopause appointment, variable HRT prescribing confidence across primary care, and a private-sector market that has filled the access gap with consultations costing several hundred pounds. Telehealth options have entered the same gap — Peppy via employer benefits, Stella as direct-to-consumer. The editorial reading: the UK pathway question is not which option is best in the abstract but which option a given reader can access at a price that works.

   Source: Wellbeing of Women / UK Parliament · 2022–2024 · UK survey + parliamentary evidence

Evidence at a glance: the UK pathway landscape

Reader questions

What can a UK GP actually do for perimenopause under NICE NG23?

Under the 2024 update of NICE NG23, a UK GP can diagnose perimenopause clinically in a woman over 45 presenting with vasomotor symptoms and a change in cycle — without a hormone test. The GP can prescribe menopausal hormone therapy in line with the guideline (transdermal oestradiol with progestogen for women with a uterus is the first-line regimen the guideline describes), discuss non-hormonal options, and refer onward where the presentation is atypical or the case is complex. What a GP cannot always offer is unhurried time, and the published evidence on UK access gaps reflects that. If the appointment feels rushed or the prescribing confidence at your practice feels low, the guideline itself supports asking for a referral to a clinician with a special interest in menopause — NHS or private. This is a conversation to have with your GP, not a decision to make from a website.

What does a private menopause clinic add that an NHS appointment does not?

What a private clinic typically adds is consultation length, continuity of clinician, and a practice that centres the menopausal transition rather than fitting it into a 10-minute primary-care slot. What it does not add is a different clinical guideline — NICE NG23 governs UK menopause prescribing whether the consultation is NHS or private. The question worth asking before booking is whether the clinician holds British Menopause Society accreditation, what the fee structure covers (initial consultation, follow-up, prescription review), and whether the clinic prescribes within the NICE NG23 framework or extends beyond it. A clinic that prescribes well outside NICE NG23 is making a clinical choice that warrants a clear conversation about evidence and risk.

Is UK telehealth a credible third pathway, or is it a marketing layer?

Both descriptions hold for parts of the UK telehealth market. Peppy (peppy.health) is the most-cited UK menopause telehealth platform; it is delivered primarily through employer benefits and partners with Wellbeing of Women, the UK women’s health charity. Stella (joinstella.com) is direct-to-consumer subscription. The credibility test is the same one as for any clinic: who are the prescribing clinicians, what accreditation do they hold, and how does the prescribing scope read against NICE NG23. A telehealth platform with BMS-accredited clinicians prescribing within the NICE NG23 framework is a clinical service delivered through a different channel; one without that backing is a content product with a consultation attached.

What about the breast cancer risk from HRT — is it as high as the headlines say?

The Collaborative Group on Hormonal Factors in Breast Cancer 2019 meta-analysis in The Lancet, drawing on 108,647 postmenopausal breast cancer cases, reports that current oestrogen-progestagen users carry a relative risk of 1.60 in years 1–4 and 2.08 in years 5–14; oestrogen-only preparations carry smaller relative risks (1.17, 1.33); vaginal oestrogens were not associated with excess risk. The population-level framing in the paper: 5 years of oestrogen-plus-daily-progestagen MHT starting at age 50 corresponds to roughly one extra breast cancer per 50 users by age 69. This is a quantified trade-off, not a verdict. The framing for a reader booking a consultation is that the right place to read this number against your own family history, baseline risk and symptom burden is with a BMS-accredited clinician — not with a website.

Why is this cluster a service review rather than a recommendation of a specific clinical treatment?

Because this is the page on the site where the answer is not a Solgar supplement and is also not a treatment recommendation. There is no supplement that replaces a clinical consultation, a NICE-aligned prescribing decision, or the longitudinal relationship a reader builds with a clinician. HerStack is published by Suggestic, a digital nutrition company; we picked Solgar UK as the reference brand for the supplement clusters where formulation matters. On this cluster the criteria that matter are different — UK availability, BMS-accredited clinicians, transparent fees, NICE NG23-aligned prescribing scope, and an honest framing of what each pathway can and cannot offer. The cards below describe options to consider and questions to ask. The clinical decision is yours to make with a clinician.

How often is this article updated?

We review each cluster page against new evidence quarterly, and update the page header date when we make a substantive change. The pathway cards below carry their own last-reviewed date so you can see when the provider fee structures and the regulatory framing were last checked.

Three pathways, with editorial rationale

Each entry carries the category, the pathway or service, the rationale, who it suits, the caveat, the price range, and the provider URL. These are editorial outbound links, not affiliate links. The clinical decision is yours.

1. Your GP, with a NICE NG23 conversation

   Category: NHS pathway · England & Wales

   Rationale: The NHS GP appointment is the canonical UK starting point for perimenopause care, and the 2024 update of NICE NG23 sits behind it. A UK GP can diagnose perimenopause clinically in women over 45, discuss MHT options including transdermal oestradiol-and-progestogen for women with a uterus, prescribe within the guideline, and refer onward where the presentation is atypical or the case is complex. The cost is free at the point of use; the pathway is the one every other UK option is benchmarked against.

   Suits: Suits: women over 45 with typical perimenopause presentations who want a clinician who knows their wider medical history, women on existing prescriptions where interactions matter, and readers who want to start inside the UK clinical guideline before considering whether a specialist consultation adds something. Reading NICE NG23 itself before the appointment is the single most useful thing a reader can do.

   Caveat: What an NHS GP appointment does not always offer is unhurried consultation time or a clinician whose practice centres on menopause specifically. Wait times for an appointment vary by area, and the published Wellbeing of Women and UK Parliament evidence sessions document a real access gap. Where the GP prescribing confidence at your practice feels low, the guideline supports asking for a referral to a clinician with a special interest in menopause — NHS or private.

   Price: Free at point of use

   Provider: https://www.nhs.uk/conditions/menopause/

2. Newson Health Menopause & Wellbeing Centre

   Category: Private menopause clinic · UK

   Rationale: Newson Health (Stratford-upon-Avon, with UK-wide remote consultations) is the most-cited UK private menopause clinic and operates with BMS-accredited specialists across its clinical team. Founded by Dr Louise Newson, it has been a significant force in UK menopause-care discourse and runs the Balance app and a published library of patient-information materials. Carded here as the reference UK private option on accreditation, transparency-of-fees and clinician-continuity grounds; readers should compare against other UK private menopause options including The Menopause Clinic London, Bupa and Spire, where the same accreditation question applies.

   Suits: Suits: women whose NHS appointment did not resolve the case, women who want a clinician whose practice centres on menopause specifically, and readers willing to pay for consultation length and continuity. Also suits readers with atypical presentations or a complex history where the time a private appointment offers translates into a more thorough conversation about MHT options, non-hormonal alternatives and follow-up cadence.

   Caveat: What a private clinic does not change is the underlying clinical guideline — NICE NG23 governs UK menopause prescribing whether the consultation is NHS or private. Any prescribing that extends well beyond NICE NG23 warrants a clear conversation about the evidence base and the trade-offs. Fees are out-of-pocket; private prescriptions are dispensed at the patient’s cost rather than through the NHS prescription charge.

   Price: Initial consultation from £325; follow-ups from £195

   Provider: https://www.newsonhealth.co.uk/

3. Peppy (UK women’s health platform)

   Category: UK telehealth · menopause programme

   Rationale: Peppy (peppy.health, UK-headquartered) delivers menopause support through employer benefits and partners with Wellbeing of Women, the UK women’s health charity, on programme content. The platform pairs one-to-one practitioner sessions with a content library and group sessions; clinical components are delivered by UK-registered clinicians. Carded here on UK regulatory framing, the third-party charity partnership, and accessibility-through-employer-benefit grounds. Readers without employer access can compare against Stella (joinstella.com), Bupa virtual GP and GP at Hand, where the same accreditation question applies.

   Suits: Suits: women whose employer offers Peppy as a benefit and who want one-to-one practitioner support outside the GP appointment, women in early perimenopause looking for a longitudinal touch-point rather than a one-off consultation, and readers who want a structured programme rather than a single visit. The third-party Wellbeing of Women partnership is a useful editorial signal for a reader weighing telehealth options.

   Caveat: What Peppy does not replace is a NICE NG23-aligned prescribing relationship with a clinician who can write you an MHT prescription on the NHS. The B2B-via-employer access route is also a real constraint — readers without employer coverage will need to look at a different telehealth option or pay direct-to-consumer. As with any telehealth platform, the question worth asking is whether the prescribing clinicians hold BMS accreditation and how the prescribing scope reads against NICE NG23.

   Price: Through employer benefit; direct-to-consumer pricing varies

   Provider: https://peppy.health/

What to look for in a clinic or service: three criteria

1. BMS-accredited clinicians. The British Menopause Society specialist register is the UK quality marker for clinicians whose practice centres on the menopausal transition. Whether a clinic is NHS, private or telehealth, the question worth asking is whether the clinician you will see holds the BMS accreditation. A clinician who does not hold it may still be excellent — but the BMS register gives you a verifiable credentials check.
2. NICE NG23-aligned prescribing scope. NICE NG23 is the UK clinical guideline for menopause prescribing and applies whether the consultation is NHS, private or telehealth. A clinic or platform that prescribes well outside the guideline is making a clinical choice that warrants a clear conversation about evidence and risk — not a refusal to consider it, but an informed conversation. Ask before you book how the prescribing scope reads against NICE NG23.
3. Transparent fees and follow-up cadence. Private and telehealth options vary widely in fee structure: initial consultation, follow-up rate, prescription review, ongoing membership. A provider whose fee structure is published clearly and whose follow-up cadence is set out in writing is operating inside the editorial criteria. A provider whose total cost only becomes clear after the initial consultation is not.

Citations

1. National Institute for Health and Care Excellence. Menopause: identification and management (NG23). NICE guideline, published November 2015, updated November 2024. nice.org.uk/guidance/ng23
2. NHS England. Menopause — diagnosis, symptoms and treatment pathways. NHS, retained 2025. nhs.uk/conditions/menopause
3. British Menopause Society. Tools for clinicians: 2024 update — including guidance on investigation, diagnosis and treatment of women in the menopausal transition, and the BMS-accredited specialist register. BMS, 2024. thebms.org.uk/tools-for-clinicians
4. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. The Lancet, 2019;394(10204):1159-1168. (Individual-participant meta-analysis, 108,647 cases.) PMID 31474332
5. Royal College of Obstetricians and Gynaecologists. Menopause and women’s health in later life — RCOG position statements and patient information. RCOG, retained 2024. rcog.org.uk/menopause
6. Wellbeing of Women. Menopause Workplace Pledge and survey programme — UK women’s health charity. Wellbeing of Women, retained 2025. wellbeingofwomen.org.uk
7. UK Parliament Women and Equalities Committee. Menopause and the workplace — first report and follow-up evidence sessions. House of Commons, 2022–2024. committees.parliament.uk/menopause-and-the-workplace
8. General Medical Council. The medical register — search for licensed UK doctors and specialist credentials. GMC, retained 2025. gmc-uk.org/the-medical-register
9. Care Quality Commission. Find a service — regulator for health and social care providers in England, including private clinics and digital primary care. CQC, retained 2025. cqc.org.uk
10. The Menopause Charity. Patient-facing information on menopause symptoms, MHT and finding a UK clinician. The Menopause Charity, retained 2025. themenopausecharity.org
11. Advertising Standards Authority / Committee of Advertising Practice. Health: medicines, medical devices, health-related products and beauty products — guidance on UK marketing of clinical services and consultations. ASA / CAP, retained 2025. asa.org.uk/advice-and-resources
12. Newson Health. Menopause & Wellbeing Centre — clinic information, consultation fees and clinical team. Newson Health Ltd., retained 2025. newsonhealth.co.uk
13. Peppy Health. Menopause programme — UK women’s health platform, partnered with Wellbeing of Women. Peppy Health Ltd., retained 2025. peppy.health
14. Suggestic. Editorial standards and methodology, HerStack. Suggestic Ltd., 2026.